56 related articles for article (PubMed ID: 30534553)
1. Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).
Kim PM; Nejati R; Lu P; Thakkar D; Mackrides N; Dupoux V; Nakhoda S; Baldwin DA; Pei J; Dave SS; Wang YL; Wasik MA
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37730436
[TBL] [Abstract][Full Text] [Related]
2. BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.
Oien DB; Sharma S; Hattersley MM; DuPont M; Criscione SW; Prickett L; Goeppert AU; Drew L; Yao Y; Zhang J; Chan HM
Blood Adv; 2023 Sep; 7(17):5108-5121. PubMed ID: 37184294
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.
Rho H; Jeong IJ; Prica A
Curr Oncol; 2023 Dec; 30(12):10488-10500. PubMed ID: 38132398
[TBL] [Abstract][Full Text] [Related]
4. STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Benoit A; Abraham MJ; Li S; Kim J; Estrada-Tejedor R; Bakadlag R; Subramaniam N; Makhani K; Guilbert C; Tu R; Salaciak M; Klein KO; Coyle KM; Hilton LK; Santiago R; Dmitrienko S; Assouline S; Morin RD; Del Rincon SV; Johnson NA; Mann KK
Int J Hematol; 2024 Mar; 119(3):275-290. PubMed ID: 38285120
[TBL] [Abstract][Full Text] [Related]
5. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.
Decruyenaere P; Offner F; Vandesompele J
Exp Hematol Oncol; 2021 Feb; 10(1):13. PubMed ID: 33593440
[TBL] [Abstract][Full Text] [Related]
6. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Dobrovolsky D; Wang ES; Morrow S; Leahy C; Faust T; Nowak RP; Donovan KA; Yang G; Li Z; Fischer ES; Treon SP; Weinstock DM; Gray NS
Blood; 2019 Feb; 133(9):952-961. PubMed ID: 30545835
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma.
Metwally AM; Kasem AAHM; Youssif MI; Hassan SM; Abdel Wahab AHA; Refaat LA
Sci Rep; 2023 Mar; 13(1):4899. PubMed ID: 36966176
[TBL] [Abstract][Full Text] [Related]
8. Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.
Dumontet E; Mancini SJC; Tarte K
Front Immunol; 2021; 12():784691. PubMed ID: 34956214
[TBL] [Abstract][Full Text] [Related]
9. Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy.
Sircar A; Chowdhury SM; Hart A; Bell WC; Singh S; Sehgal L; Epperla N
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019190
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
11. Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma.
Turturro F
Biomed Res Int; 2015; 2015():484537. PubMed ID: 25984532
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
[TBL] [Abstract][Full Text] [Related]
13. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
15. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
